What is Teriparatide?
Teriparatide is a parathyroid-hormone-related medicine used in osteoporosis care. Fracture reduction is a more direct clinical outcome than a bone marker alone.
Biological role or research focus
Parathyroid-hormone-related bone formation.
The relevant clinical setting is osteoporosis with high fracture risk, not broad performance enhancement.
Role reference: MedlinePlus · Teriparatide ↗
Names you may encounter
Forteo
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- PTH(1–34) analogue
- Main research area
- Bone formation and fracture prevention
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Teriparatide ↗
Quick answers
- Is Teriparatide FDA approved?
- Yes. Forteo (NDA 021318, approved 2002), Bonsity and other teriparatide injections for osteoporosis at high fracture risk. Source ↗
- Is Teriparatide safe?
- Teriparatide builds bone in osteoporosis; joint pain and nausea are common, and the label warns of bone cancer (osteosarcoma) seen in rats, high calcium and dizziness on standing. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Teriparatide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Fracture Prevention Trial (2001) | Human randomized trial | 1,637 postmenopausal women with prior vertebral fractures. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2001
Fracture Prevention Trial
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
- Population / model
- 1,637 postmenopausal women with prior vertebral fractures.
- Study design
- Two PTH(1–34) groups versus placebo; median observation 21 months.
- Main finding
- New vertebral fractures occurred in 14% with placebo versus 5% and 4% in the active groups. Bone mineral density also increased.
- Limits & context
- This is fracture-prevention evidence in osteoporosis. It does not establish accelerated healing of every sports injury or benefit in people with normal bone density.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
84 registered studies name Teriparatide as an intervention among the 100 most recently updated of 182 search results; 11 are recruiting or under way, 3 have not started recruiting yet, 51 completed and 19 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Combined Anabolic Therapy NCT06558188 · Massachusetts General Hospital | Recruiting | Phase 4 | 2025-02-03 | 50 |
| PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot) NCT06303284 · University of Calgary | Not yet recruiting | Phase 1 / Phase 2 | 2027-03-15 | 54 |
| Novel Combination Therapy for Osteoporosis in Men NCT03994172 · VA Office of Research and Development | Completed | Phase 4 | 2019-07-01 | 40 |
| Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis NCT07242612 · Khyber Medical University Peshawar | Completed | Not applicable | 2025-10-01 | 40 |
| Sequential Therapies After Osteoanabolic Treatment NCT06164795 · 424 General Military Hospital | Recruiting | 2023-11-25 | 150 | |
| Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid NCT03735537 · University of Edinburgh | Completed | Phase 4 | 2016-11-01 | 350 |
| Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action NCT01293292 · Sheffield Teaching Hospitals NHS Foundation Trust | Completed | Phase 4 | 2011-01 | 19 |
| Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover NCT05151484 · Madhumathi Rao | Active, not recruiting | Phase 4 | 2022-03-21 | 60 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 84 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. ↗
Lancet (London, England) · 2015 Sep 19 · Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Read available full text ↗
Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. ↗
Medicine · 2017 May · Comparative Study, Journal Article, Meta-Analysis, Systematic Review
Read available full text ↗
Teriparatide. ↗
· 2012 · Review
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. ↗
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025 Jun · Journal Article, Network Meta-Analysis, Systematic Review
Read available full text ↗
Risks & interactions
Teriparatide builds bone in osteoporosis; joint pain and nausea are common, and the label warns of bone cancer (osteosarcoma) seen in rats, high calcium and dizziness on standing.
Safety is established by FDA labeling and long clinical use. Observational studies in people have not shown a higher osteosarcoma risk, but data beyond two years of use are limited. It is not approved for children.
Take extra care with: Heart or blood pressure problemsCancer, now or in the pastKidney problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- History of severe allergy to teriparatide or any ingredient
- Higher osteosarcoma risk, such as Paget's disease, bone cancer or bone metastases, or past radiation to the skeleton: label says avoid
- Children and young adults whose growth plates are still open: label says avoid
- Underlying high-calcium disorders: label says avoid
Interactions
- Digoxin: temporary rises in blood calcium may increase the risk of digoxin toxicity
Serious risks
- Osteosarcoma (bone cancer) in rats, with rare reports in people
- Severe allergic reactions, including anaphylaxis and angioedema
- High blood calcium and worsening skin calcification
- Worsening kidney stones
- Dizziness or fainting on standing (orthostatic hypotension)
Common side effects
- joint pain
- pain
- nausea
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Forteo (teriparatide) prescribing information ↗
Key precautions
Elevated calcium, kidney stones, dizziness, and specific bone-cancer risk factors require review. Prior skeletal radiation and other bone disorders can affect suitability.
Source: MedlinePlus · Teriparatide ↗
Regulatory status
- U.S. FDA approval
- Approved
Forteo (NDA 021318, approved 2002), Bonsity and other teriparatide injections for osteoporosis at high fracture risk. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The medication reference describes osteoporosis treatment in selected patients. The trial below concerns postmenopausal women with previous vertebral fractures, a population with substantial baseline risk.
Source: MedlinePlus · Teriparatide ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
Its therapeutic action promotes bone formation and increases bone strength and density. Those actions are studied in a defined bone-disease context.
Source: MedlinePlus · Teriparatide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- The relevant clinical setting is osteoporosis with high fracture risk, not broad performance enhancement.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does fracture prevention prove faster healing of an existing injury?
No. Preventing a new fracture and healing an existing one are different clinical questions.
Source: MedlinePlus · Teriparatide ↗
Can the trial results be applied to people with normal bone density?
Not directly. Baseline risk and the condition being treated strongly affect benefit and harm.
References & editorial record
- MedlinePlus · Teriparatide ↗
- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
